blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3173092

EP3173092 - RNA CONTAINING COMPOSITION FOR TREATMENT OF TUMOR DISEASES [Right-click to bookmark this link]
StatusPatent revoked
Status updated on  05.07.2024
Database last updated on 03.04.2025
FormerThe patent has been granted
Status updated on  24.05.2019
FormerGrant of patent is intended
Status updated on  12.05.2019
FormerExamination is in progress
Status updated on  27.07.2018
FormerRequest for examination was made
Status updated on  23.03.2018
FormerThe application has been published
Status updated on  28.04.2017
Most recent event   Tooltip05.07.2024Revocation of patentpublished on 07.08.2024  [2024/32]
Applicant(s)For all designated states
CureVac SE
Friedrich-Miescher-Straße 15
72076 Tübingen / DE
[2023/01]
Former [2021/10]For all designated states
CureVac AG
Friedrich-Miescher-Straße 15
72076 Tübingen / DE
Former [2017/22]For all designated states
CureVac AG
Paul-Ehrlich-Str. 15
72076 Tübingen / DE
Inventor(s)01 / Fotin-Mleczek, Mariola
c/o IP Department
CureVac AG
Paul Ehrlich Str. 15
72706 Tübingen / DE
02 / Kowalczyk, Aleksandra
c/o IP Department
CureVac AG
Paul Ehrlich Str. 15
72706 Tübingen / DE
03 / Heidenreich, Regina
c/o IP Department
CureVac AG
Paul Ehrlich Str. 15
72076 Tübingen / DE
04 / Baumhof, Patrick
c/o IP Department
CureVac AG
Paul Ehrlich Str. 15
72706 Tübingen / DE
05 / Probst, Jochen
c/o IP Department
CureVac AG
Paul Ehrlich Str. 15
72706 Tübingen / DE
06 / Kallen, Karl-Josef
c/o IP Department
CureVac AG
Paul Ehrlich Str. 15
72706 Tübingen / DE
 [2019/26]
Former [2017/22]01 / Fotin-Mleczek, Mariola
Chemnitzer Weg 10
71065 Sindelfingen / DE
02 / Kowalczyk, Aleksandra
Ostendstr. 82
70188 Stuttgart / DE
03 / Heidenreich, Regina
Birkenstr. 15
72072 Tübingen / DE
04 / Baumhof, Patrick
Erlenstr. 28
72144 Dusslingen / DE
05 / Probst, Jochen
Kirchhofländern 19
72649 Wolfschlugen / DE
06 / Kallen, Karl-Josef
Marienhofer Weg 24
50226 Königsdorf / DE
Representative(s)Graf von Stosch, Andreas, et al
Graf von Stosch
Patentanwaltsgesellschaft mbH
Prinzregentenstraße 22
80538 München / DE
[2019/26]
Former [2017/22]Berger, Michael, et al
Graf von Stosch Patentanwaltsgesellschaft mbH
Prinzregentenstr. 22
80538 München / DE
Application number, filing date16166757.122.04.2016
[2017/22]
Priority number, dateEP2015000119122.04.2015         Original published format: EP 15001191
[2017/22]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report 
No.:EP3173092
Date:31.05.2017
Language:EN
[2017/22]
Type: A3 Search report 
No.:EP3173092
Date:20.09.2017
Language:EN
[2017/38]
Type: B1 Patent specification 
No.:EP3173092
Date:26.06.2019
Language:EN
[2019/26]
Search report(s)(Supplementary) European search report - dispatched on:EP23.08.2017
ClassificationIPC:A61K38/19, A61K31/7105, C07K14/52, A61K38/20, A61K39/00, C12N15/113, C12N15/117, A61P35/00
[2019/20]
CPC:
A61K31/7105 (EP,RU,US); A61K48/005 (CN,KR,US); A61K31/7088 (CN);
A61K31/713 (EP,US); A61K38/177 (EP,CN,KR,US); A61K38/1774 (EP,CN,US);
A61K38/19 (EP,CN,KR,RU,US); A61K38/191 (US); A61K38/20 (CN);
A61K38/208 (EP,KR,US); A61K39/0011 (CN); A61K39/12 (EP,US);
A61K39/145 (US); A61K39/39 (EP,US); A61K39/3955 (EP,KR,US);
A61K39/39558 (CN,KR,US); A61K45/06 (CN,KR,US); A61K48/0025 (US);
A61K48/0041 (KR,US); A61K9/0019 (CN,US); A61P35/00 (EP);
A61P43/00 (EP); C07K16/2818 (EP,KR,US); C07K16/2878 (US);
C07K16/2896 (EP,US); C07K16/30 (US); C07K16/34 (EP,US);
C12N15/113 (RU); C12N15/117 (KR,US); C12N7/00 (US);
C12Q1/6806 (RU); A61K2039/53 (EP,CN,US); A61K2039/54 (EP,CN,US);
A61K2039/55511 (EP,CN,US); A61K2039/55522 (EP,CN,US); A61K2039/55538 (EP,CN,US);
A61K2039/55561 (EP,US); A61K2039/585 (EP,CN,US); A61K2300/00 (KR);
C07K2317/75 (US); C07K2317/76 (US); C12N2310/17 (US);
C12N2320/30 (US); C12N2760/16034 (US); C12N2760/16134 (EP,US);
Y02A50/30 (EP,US) (-)
C-Set:
A61K31/7088, A61K2300/00 (CN);
A61K38/1774, A61K2300/00 (CN);
A61K38/177, A61K2300/00 (CN);
A61K38/19, A61K2300/00 (CN);
A61K38/20, A61K2300/00 (CN);
A61K39/0011, A61K2300/00 (CN);
A61K39/39558, A61K2300/00 (CN);
A61K39/3955, A61K2300/00 (EP,US)
(-)
Former IPC [2017/22]A61K38/19, C07K14/52, A61K38/20, A61K39/00, C12N15/113, C12N15/117, A61P35/00
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2018/17]
Former [2017/22]AL,  AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  RS,  SE,  SI,  SK,  SM,  TR 
Extension statesBA19.03.2018
ME19.03.2018
TitleGerman:RNA-HALTIGE ZUSAMMENSETZUNG ZUR BEHANDLUNG VON TUMORERKRANKUNGEN[2017/22]
English:RNA CONTAINING COMPOSITION FOR TREATMENT OF TUMOR DISEASES[2017/22]
French:COMPOSITION CONTENANT UN ARN POUR LE TRAITEMENT DE MALADIES TUMORALES[2017/22]
Examination procedure22.04.2016Date on which the examining division has become responsible
02.08.2016Loss of particular rights, legal effect: Claims
26.09.2016Despatch of communication of loss of particular rights: Claims {1}
16.03.2018Amendment by applicant (claims and/or description)
16.03.2018Examination requested  [2018/17]
12.06.2018Observations by third parties
26.07.2018Despatch of a communication from the examining division (Time limit: M04)
05.12.2018Reply to a communication from the examining division
11.02.2019Despatch of a communication from the examining division (Time limit: M02)
15.02.2019Reply to a communication from the examining division
05.03.2019Observations by third parties
13.05.2019Communication of intention to grant the patent
20.05.2019Fee for grant paid
20.05.2019Fee for publishing/printing paid
20.05.2019Receipt of the translation of the claim(s)
Divisional application(s)EP17196250.9  / EP3326641
EP19181044.9  / EP3603661
Opposition(s)Opponent(s)01  26.03.2020  30.03.2020  ADMISSIBLE
eTheRNA Immunotherapies NV
Galileilaan 19
2845 Niel / BE
Opponent's representative
Arnold & Siedsma
Bezuidenhoutseweg 57
2594 AC The Hague / NL
 02  26.03.2020  24.05.2023  WITHDRAWN
Friedrich, Rainer
Breuer Friedrich Hahner Patentanwälte PartG mbB
Brienner Straße 1
80333 München / DE
Opponent's representative
Friedrich, Rainer
CSL Behring GmbH
Emil-von-Behring-Straße 76
35041 Marburg / DE
 03  26.03.2020  30.03.2020  ADMISSIBLE
BioNTech RNA Pharmaceuticals GmbH
An der Goldgrube 12
55131 Mainz / DE
Opponent's representative
Thomann, William John
ZSP
Patentanwälte PartG mbB
Hansastraße 32
80686 München / DE
 04  26.03.2020  30.03.2020  ADMISSIBLE
König Szynka Tilmann von Renesse
Patentanwälte Partnerschaft mbB
Mönchenwerther Strasse 11
40545 Düsseldorf / DE
Opponent's representative
Hoffmann Eitle
Patent- und Rechtsanwälte PartmbB
Arabellastraße 30
81925 München / DE
 05  26.03.2020  11.01.2024  WITHDRAWN
SANOFI
54 rue La Boétie
75008 Paris / FR
Opponent's representative
Lavoix
2, place d'Estienne d'Orves
75441 Paris Cedex 09 / FR
 [2024/08]
Former [2023/26]
Opponent(s)01  26.03.2020  30.03.2020  ADMISSIBLE
eTheRNA Immunotherapies NV
Galileilaan 19
2845 Niel / BE
Opponent's representative
Arnold & Siedsma
Bezuidenhoutseweg 57
2594 AC The Hague / NL
 02  26.03.2020  24.05.2023  WITHDRAWN
Friedrich, Rainer
Breuer Friedrich Hahner Patentanwälte PartG mbB
Brienner Straße 1
80333 München / DE
Opponent's representative
Friedrich, Rainer
CSL Behring GmbH
Emil-von-Behring-Straße 76
35041 Marburg / DE
 03  26.03.2020  30.03.2020  ADMISSIBLE
BioNTech RNA Pharmaceuticals GmbH
An der Goldgrube 12
55131 Mainz / DE
Opponent's representative
Thomann, William John
ZSP
Patentanwälte PartG mbB
Hansastraße 32
80686 München / DE
 04  26.03.2020  30.03.2020  ADMISSIBLE
König Szynka Tilmann von Renesse
Patentanwälte Partnerschaft mbB
Mönchenwerther Strasse 11
40545 Düsseldorf / DE
Opponent's representative
Hoffmann Eitle
Patent- und Rechtsanwälte PartmbB
Arabellastraße 30
81925 München / DE
 05  26.03.2020  30.03.2020  ADMISSIBLE
SANOFI
54 rue La Boétie
75008 Paris / FR
Opponent's representative
Lavoix
2, place d'Estienne d'Orves
75441 Paris Cedex 09 / FR
Former [2022/18]
Opponent(s)01  26.03.2020  30.03.2020  ADMISSIBLE
eTheRNA Immunotherapies NV
Galileilaan 19
2845 Niel / BE
Opponent's representative
Arnold & Siedsma
Bezuidenhoutseweg 57
2594 AC The Hague / NL
 02  26.03.2020  30.03.2020  ADMISSIBLE
Friedrich, Rainer
Breuer Friedrich Hahner Patentanwälte PartG mbB
Brienner Straße 1
80333 München / DE
Opponent's representative
Friedrich, Rainer
Brienner Straße 1
80333 München / DE
 03  26.03.2020  30.03.2020  ADMISSIBLE
BioNTech RNA Pharmaceuticals GmbH
An der Goldgrube 12
55131 Mainz / DE
Opponent's representative
Thomann, William John
ZSP
Patentanwälte PartG mbB
Hansastraße 32
80686 München / DE
 04  26.03.2020  30.03.2020  ADMISSIBLE
König Szynka Tilmann von Renesse
Patentanwälte Partnerschaft mbB
Mönchenwerther Strasse 11
40545 Düsseldorf / DE
Opponent's representative
Hoffmann Eitle
Patent- und Rechtsanwälte PartmbB
Arabellastraße 30
81925 München / DE
 05  26.03.2020  30.03.2020  ADMISSIBLE
SANOFI
54 rue La Boétie
75008 Paris / FR
Opponent's representative
Lavoix
2, place d'Estienne d'Orves
75441 Paris Cedex 09 / FR
Former [2021/44]
Opponent(s)01  26.03.2020  30.03.2020  ADMISSIBLE
eTheRNA Immunotherapies NV
Galileilaan 19
2845 Niel / BE
Opponent's representative
Arnold & Siedsma
Bezuidenhoutseweg 57
2594 AC The Hague / NL
 02  26.03.2020  30.03.2020  ADMISSIBLE
Friedrich, Rainer
Breuer Friedrich Hahner Patentanwälte PartG mbB
Brienner Straße 1
80333 München / DE
Opponent's representative
Friedrich, Rainer
Breuer Friedrich Hahner
Patentanwälte PartG mbB i. Gr.
Brienner Strasse 1
80333 München / DE
 03  26.03.2020  30.03.2020  ADMISSIBLE
BioNTech RNA Pharmaceuticals GmbH
An der Goldgrube 12
55131 Mainz / DE
Opponent's representative
Thomann, William John
ZSP
Patentanwälte PartG mbB
Hansastraße 32
80686 München / DE
 04  26.03.2020  30.03.2020  ADMISSIBLE
König Szynka Tilmann von Renesse
Patentanwälte Partnerschaft mbB
Mönchenwerther Strasse 11
40545 Düsseldorf / DE
Opponent's representative
Hoffmann Eitle
Patent- und Rechtsanwälte PartmbB
Arabellastraße 30
81925 München / DE
 05  26.03.2020  30.03.2020  ADMISSIBLE
SANOFI
54 rue La Boétie
75008 Paris / FR
Opponent's representative
Lavoix
2, place d'Estienne d'Orves
75441 Paris Cedex 09 / FR
Former [2021/16]
Opponent(s)01  26.03.2020  30.03.2020  ADMISSIBLE
eTheRNA Immunotherapies NV
Galileilaan 19
2845 Niel / BE
Opponent's representative
Arnold & Siedsma
Bezuidenhoutseweg 57
2594 AC The Hague / NL
 02  26.03.2020  30.03.2020  ADMISSIBLE
Friedrich, Rainer
Breuer Friedrich Hahner Patentanwälte PartG mbB
Brienner Straße 1
80333 München / DE
Opponent's representative
Friedrich, Rainer
Breuer Friedrich Hahner
Patentanwälte PartG mbB i. Gr.
Brienner Strasse 1
80333 München / DE
 03  26.03.2020  30.03.2020  ADMISSIBLE
BioNTech RNA Pharmaceuticals GmbH
An der Goldgrube 12
55131 Mainz / DE
Opponent's representative
Thomann, William John
ZSP
Patentanwälte PartG mbB
Hansastraße 32
80686 München / DE
 04  26.03.2020  30.03.2020  ADMISSIBLE
König Szynka Tilmann von Renesse
Patentanwälte Partnerschaft mbB
Mönchenwerther Strasse 11
40545 Düsseldorf / DE
Opponent's representative
Roth, Carla
König-Szynka-Tilmann-von Renesse
Patentanwälte Partnerschaft mbB
Mönchenwerther Straße 11
40545 Düsseldorf / DE
 05  26.03.2020  30.03.2020  ADMISSIBLE
SANOFI
54 rue La Boétie
75008 Paris / FR
Opponent's representative
Lavoix
2, place d'Estienne d'Orves
75441 Paris Cedex 09 / FR
Former [2020/19]
Opponent(s)01  26.03.2020  30.03.2020  ADMISSIBLE
eTheRNA Immunotherapies NV
Galileilaan 19
2845 Niel / BE
Opponent's representative
LC Patents
Kempische Steenweg 542A
3500 Hasselt / BE
 02  26.03.2020  30.03.2020  ADMISSIBLE
Friedrich, Rainer
Breuer Friedrich Hahner Patentanwälte PartG mbB
Brienner Straße 1
80333 München / DE
Opponent's representative
Friedrich, Rainer
Breuer Friedrich Hahner
Patentanwälte PartG mbB i. Gr.
Brienner Strasse 1
80333 München / DE
 03  26.03.2020  30.03.2020  ADMISSIBLE
BioNTech RNA Pharmaceuticals GmbH
An der Goldgrube 12
55131 Mainz / DE
Opponent's representative
Thomann, William John
ZSP
Patentanwälte PartG mbB
Hansastraße 32
80686 München / DE
 04  26.03.2020  30.03.2020  ADMISSIBLE
König Szynka Tilmann von Renesse
Patentanwälte Partnerschaft mbB
Mönchenwerther Strasse 11
40545 Düsseldorf / DE
Opponent's representative
Roth, Carla
König-Szynka-Tilmann-von Renesse
Patentanwälte Partnerschaft mbB
Mönchenwerther Straße 11
40545 Düsseldorf / DE
 05  26.03.2020  30.03.2020  ADMISSIBLE
SANOFI
54 rue La Boétie
75008 Paris / FR
Opponent's representative
Lavoix
2, place d'Estienne d'Orves
75441 Paris Cedex 09 / FR
18.06.2020Invitation to proprietor to file observations on the notice of opposition
28.12.2020Reply of patent proprietor to notice(s) of opposition
15.12.2021Date of oral proceedings
15.12.2021Legal effect of revocation of patent [2024/32]
09.02.2022Despatch of minutes of oral proceedings
09.02.2022Despatch of communication that the patent will be revoked
Appeal following opposition24.03.2022Appeal received No.  T0786/22
24.03.2022Payment of appeal fee
15.06.2022Statement of grounds filed
26.06.2024Result of appeal procedure: REVOCATION OF PATENT AT PROPRIETOR'S REQUEST
27.06.2024Despatch of the decision of the Board of Appeal
Fees paidRenewal fee
02.03.2018Renewal fee patent year 03
20.03.2019Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU22.04.2016
AL26.06.2019
CY26.06.2019
CZ26.06.2019
EE26.06.2019
HR26.06.2019
LT26.06.2019
LV26.06.2019
MC26.06.2019
MK26.06.2019
MT26.06.2019
PL26.06.2019
RO26.06.2019
RS26.06.2019
SI26.06.2019
SK26.06.2019
SM26.06.2019
TR26.06.2019
BG26.09.2019
GR27.09.2019
IS26.10.2019
PT28.10.2019
LU22.04.2020
[2022/32]
Former [2022/28]HU22.04.2016
AL26.06.2019
CY26.06.2019
CZ26.06.2019
EE26.06.2019
HR26.06.2019
LT26.06.2019
LV26.06.2019
MC26.06.2019
MT26.06.2019
PL26.06.2019
RO26.06.2019
RS26.06.2019
SI26.06.2019
SK26.06.2019
SM26.06.2019
TR26.06.2019
BG26.09.2019
GR27.09.2019
IS26.10.2019
PT28.10.2019
LU22.04.2020
Former [2021/08]AL26.06.2019
CZ26.06.2019
EE26.06.2019
HR26.06.2019
LT26.06.2019
LV26.06.2019
MC26.06.2019
PL26.06.2019
RO26.06.2019
RS26.06.2019
SI26.06.2019
SK26.06.2019
SM26.06.2019
TR26.06.2019
BG26.09.2019
GR27.09.2019
IS26.10.2019
PT28.10.2019
LU22.04.2020
Former [2020/52]AL26.06.2019
CZ26.06.2019
EE26.06.2019
HR26.06.2019
LT26.06.2019
LV26.06.2019
MC26.06.2019
PL26.06.2019
RO26.06.2019
RS26.06.2019
SI26.06.2019
SK26.06.2019
SM26.06.2019
TR26.06.2019
BG26.09.2019
GR27.09.2019
IS26.10.2019
PT28.10.2019
Former [2020/37]AL26.06.2019
CZ26.06.2019
EE26.06.2019
HR26.06.2019
LT26.06.2019
LV26.06.2019
PL26.06.2019
RO26.06.2019
RS26.06.2019
SI26.06.2019
SK26.06.2019
SM26.06.2019
TR26.06.2019
BG26.09.2019
GR27.09.2019
IS26.10.2019
PT28.10.2019
Former [2020/36]AL26.06.2019
CZ26.06.2019
EE26.06.2019
HR26.06.2019
LT26.06.2019
LV26.06.2019
PL26.06.2019
RO26.06.2019
RS26.06.2019
SK26.06.2019
SM26.06.2019
TR26.06.2019
BG26.09.2019
GR27.09.2019
IS26.10.2019
PT28.10.2019
Former [2020/24]AL26.06.2019
CZ26.06.2019
EE26.06.2019
HR26.06.2019
LT26.06.2019
LV26.06.2019
PL26.06.2019
RO26.06.2019
RS26.06.2019
SK26.06.2019
SM26.06.2019
TR26.06.2019
BG26.09.2019
GR27.09.2019
PT28.10.2019
IS24.02.2020
Former [2020/17]AL26.06.2019
CZ26.06.2019
EE26.06.2019
HR26.06.2019
LT26.06.2019
LV26.06.2019
RO26.06.2019
RS26.06.2019
SK26.06.2019
SM26.06.2019
TR26.06.2019
BG26.09.2019
GR27.09.2019
IS26.10.2019
PT28.10.2019
Former [2020/14]AL26.06.2019
CZ26.06.2019
EE26.06.2019
HR26.06.2019
LT26.06.2019
LV26.06.2019
RO26.06.2019
RS26.06.2019
SK26.06.2019
SM26.06.2019
BG26.09.2019
GR27.09.2019
IS26.10.2019
PT28.10.2019
Former [2020/12]AL26.06.2019
CZ26.06.2019
EE26.06.2019
HR26.06.2019
LT26.06.2019
LV26.06.2019
RO26.06.2019
RS26.06.2019
SK26.06.2019
BG26.09.2019
GR27.09.2019
IS26.10.2019
PT28.10.2019
Former [2020/11]AL26.06.2019
CZ26.06.2019
EE26.06.2019
HR26.06.2019
LT26.06.2019
LV26.06.2019
RO26.06.2019
RS26.06.2019
SK26.06.2019
BG26.09.2019
GR27.09.2019
PT28.10.2019
Former [2020/10]AL26.06.2019
CZ26.06.2019
HR26.06.2019
LT26.06.2019
LV26.06.2019
RO26.06.2019
RS26.06.2019
BG26.09.2019
GR27.09.2019
PT28.10.2019
Former [2020/09]AL26.06.2019
CZ26.06.2019
HR26.06.2019
LT26.06.2019
LV26.06.2019
RS26.06.2019
BG26.09.2019
GR27.09.2019
Former [2019/51]AL26.06.2019
HR26.06.2019
LT26.06.2019
LV26.06.2019
RS26.06.2019
BG26.09.2019
GR27.09.2019
Former [2019/50]AL26.06.2019
HR26.06.2019
LT26.06.2019
LV26.06.2019
RS26.06.2019
GR27.09.2019
Former [2019/47]LT26.06.2019
Documents cited:Search[XYI]WO0162274  (INST CIENTIFICO TECNOL NAVARRA [ES], et al);
 [XDYI]WO02098443  (VON DER MUELBE FLORIAN [DE], et al);
 [XYI]WO2006024518  (CUREVAC GMBH [DE], et al);
 [XYI]WO2009034172  (UNIV BRUXELLES [BE], et al);
 [XYI]WO2009149539  (UNIV MONTREAL [CA], et al);
 [Y]EP2623121  (BAYER INNOVATION GMBH [DE], et al);
 [IDY]WO2014127917  (CUREVAC GMBH [DE]);
ExaminationUS2003118564
by applicantWO9512673
 WO9521251
 WO9521915
 EP1083232
 WO02098443
 WO03051401
 WO03086280
 WO2006008154
 US7074596
 WO2008016473
 WO2008077592
 WO2008083949
 WO2008157688
 WO2009030481
 WO2009149253
 WO2010037539
 WO2011015347
 WO2011026641
 WO2012013326
 WO2012019780
 WO2012113513
 WO2012116811
 WO2013059475
 WO2013143700
 WO2014127917
 WO2014189805
otherUS2003118564
OppositionEP2700708
 WO02098443
 US2003118564
 WO03051401
 WO03059381
 WO2004004743
 WO2006008154
 WO2006024518
 WO2006122828
 WO2009046738
 WO2009046739
 WO2010037408
 WO2012116715
 WO2012116714
 WO2013053775
 WO2014127917
 WO2015024664
 WO2015024666
 WO2004035799
 WO2012006376
 WO2017123675
 WO2009095226
 WO2015048744
 WO2013120497
 WO0162274
 WO2009034172
 WO2009149539
 EP2623121
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.